3027663-77-7
Chemical Structure
B18 peptide
- CAS No.: 3027663-77-7
- Formula:C78H121N23O28S2
- Molecular Weight:1893.06
SMILES: O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CNC=N2)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@@H](CCSC)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN
Biological Activity: B18 peptide is a cationic amphipathic α-helical peptidomimetic that binds to the BST-2 extracellular domain and forms a stable complex through intermolecular hydrogen bonds near the N-terminus. B18 peptide competitively inhibits the binding of BST-2 to the extracellular matrix via its extracellular domain, reducing migrasome formation. B18 peptide induces membrane lysis through the formation of pores/water channels and annular pores, impairing membrane integrity. B18 peptide exhibits anticancer activity against breast cancer. B18 peptide can be used for research on breast cancer[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
B18 peptide | B18 peptide is a cationic amphipathic α-helical peptidomimetic that binds to the BST-2 extracellular domain and forms a stable complex through intermolecular hydrogen bonds near the N-terminus. B18 peptide competitively inhibits the binding of BST-2 to the extracellular matrix via its extracellular domain, reducing migrasome formation. B18 peptide induces membrane lysis through the formation of pores/water channels and annular pores, impairing membrane integrity. B18 peptide exhibits anticancer activity against breast cancer. B18 peptide can be used for research on breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lyu Y, et al. Development of a Cationic Amphiphilic Helical Peptidomimetic (B18L) As A Novel Anti-Cancer Drug Lead. Cancers. 2020 Aug 28;12(9):2448.
- [2]. Li X, et al. GPI‑anchored protein nanoclusters license migrasome expansion and serve as exocytic platforms for migrasome. Nat Commun. 2026 Jun 4;17(1):7162. [Content Brief]
- [3]. Lyu Y, et al. Development and Characterization of the Shortest Anti-Adhesion Peptide Analogue of B49Mod1. Molecules (Basel, Switzerland). 2020 Mar 06;25(5):1188.
